Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 1-5

  Tafani, Marco ^a,b   De Santis, Elena ^a   Coppola, Luigi ^c   Perrone, Giulietta A ^c   Carnevale, Ilaria ^a   Russo, Andrea ^d   Pucci, Bruna ^b   Carpi, Angelo ^e   Bizzarri, Mariano ^a   Russo, Matteo A ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Cellular and molecular rehabilitation; ER ; HIF 1 ; Hypoxia; Inflammation; NF B; Reprogramming cancer cells; Thyroid Cancer

Indexed keywords

CELLULAR AND MOLECULAR REHABILITATION; ER-Α; HIF-1Α; HYPOXIA; INFLAMMATION; NF-ΚB; REPROGRAMMING CANCER CELLS; THYROID CANCER;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DISEASE PROGRESSION; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; MALE; NF-KAPPA B; RECEPTORS, ESTROGEN; THYROID NEOPLASMS;

EID: 84895069258     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.10.013     Document Type: Review

References (53)

1. Boelaert K. Thyroid gland: revised guidelines for the management of thyroid cancer. Nat Rev Endocrinol 2010, 6:185-186.
2. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142.
3. Bommarito A., Richiusa P., Carissimi E., Pizzolanti G., Rodolico V., Zito G., et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer 2011, 18:669-685.
4. Liu D., Liu Z., Condouris S., Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007, 92:2264-2271.
5. Nikiforov Y.E. Molecular analysis of thyroid tumors. Mod Pathol 2011, 24(Suppl. 2):S34-S43.
6. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004, 5:875-885.
7. Santoro M., Melillo R.M., Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006, 155:645-653.
8. Miyagi E., Braga-Basaria M., Hardy E., Vasko V., Burman K.D., Jhiang S., et al. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 2004, 41:98-107.
9. Vitale M. Rethinking the role of oncogenes in papillary thyroid cancer initiation. Front Endocrinol (Lausanne) 2012, 3:83.
10. Marotta V., Guerra A., Zatelli M.C., Uberti E.D., Stasi V.D., Faggiano A., et al. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. Clin Endocrinol (Oxf) 2013, 79:733-738. 10.1111/cen.12194.
11. Guerra A., Fugazzola L., Marotta V., Cirillo M., Rossi S., Cirello V., et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 2012, 97:2333-2340.
12. Todaro M., Iovino F., Eterno V., Cammareri P., Gambara G., Espina V., et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010, 70:8874-8885.
13. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012, 33:207-214.
14. Chen G.G., Vlantis A.C., Zeng Q., van Hasselt C.A. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 2008, 8:367-377.
15. Kumar A., Klinge C.M., Goldstein R.E. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol 2010, 36:1067-1080.
16. Rajoria S., Suriano R., George A.L., Shanmugam A., Jussim C., Shin E.J., et al. Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomed Pharmacother 2012, 66:151-158.
17. Bertout J.A., Patel S.A., Simon M.C. The impact of O2 availability on human cancer. Nat Rev Cancer 2008, 8:967-975.
18. Burrows N., Resch J., Cowen R.L., von Wasielewski R., Hoang-Vu C., West C.M., et al. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer 2010, 17:61-72.
19. Turner H.E., Harris A.L., Melmed S., Wass J.A. Angiogenesis in endocrine tumors. Endocr Rev 2003, 24:600-632.
20. Celano M., Sponziello M., Tallini G., Maggisano V., Bruno R., Dima M., et al. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. Endocrine 2013, 43:147-153.
21. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
22. Tafani M., Schito L., Pellegrini L., Villanova L., Marfe G., Anwar T., Hypoxia-increased R.A.G.E., et al. and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis 2011, 32:1167-1175.
23. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
24. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Guarino V., Castellone M.D., Avilla E., Melillo R.M. Thyroid cancer and inflammation. Mol Cell Endocrinol 2010, 321:94-102.
27. Shiao S.L., Ganesan A.P., Rugo H.S., Coussens L.M. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011, 25:2559-2572.
28. Balkwill F., Coussens L.M. An inflammatory link. Nature 2004, 431:405-406.
29. Karin M. Nuclear factor-kB in cancer development and progression. Nature 2006, 441:431-436.
30. De Santis E., Di Vito M., Perrone G.A., Mari E., Osti M., De Antoni E., et al. Overexpression of pro-inflammatory genes and down-regulation of SOCS-1 in human PTC and in hypoxic BCPAP cells. Biomed Pharmacother 2013, 67:7-16.
31. Li X., Abdel-Mageed A.B., Mondal D., Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid 2013, 23:209-218.
32. Bruning U., Fitzpatrick S.F., Frank T., Birtwistle M., Taylor C.T., Cheong A. NFκB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci 2012, 69:1319-1329.
33. Nilsson S., Mäkelä S., Treuter E., Tujague M., Thomsen J., Andersson G., et al. Mechanisms of estrogen action. Physiol Rev 2001, 81:1535-1565.
34. Biswas D.K., Singh S., Shi Q., Pardee A.B., Iglehart J.D. Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE 2005, 288:e27.
35. Vanacker J.M., Pettersson K., Gustafsson J.A., Laudet V. Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J 1999, 18:4270-4279.
36. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87:905-931.
37. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
38. Vivacqua A., Bonofiglio D., Recchia A.G., Musti A.M., Picard D., Andò S., et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006, 20:631-646.
39. Santin A.P., Furlanetto T.W. Role of estrogen in thyroid function and growth regulation. J Thyroid Res 2011, 875125.
40. Chen G.G., Zeng Q., Tse G.M. Estrogen and its receptors in cancer. Med Res Rev 2008, 28:954-974.
41. Wu F., Xu R., Kim K., Martin J., Safe S. In vivo profiling of estrogen receptor/specificity protein-dependent transactivation. Endocrinology 2008, 149:5696-5705.
42. Zeng Q., Chen G.G., Vlantis A.C., van Hasselt C.A. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif 2007, 40:921-935.
43. Rajoria S., Suriano R., Shanmugam A., Wilson Y.L., Schantz S.P., Geliebter J., et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010, 20:33-41.
44. Dalla Valle L., Ramina A., Vianello S., Fassina A., Belvedere P., Colombo L. Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J Clin Endocrinol Metab 1998, 83:3702-3709.
45. Di Vito M., De Santis E., Perrone G.A., Mari E., Giordano M.C., De Antoni E., et al. Overexpression of estrogen receptor-α in human papillary thyroid carcinomas studied by laser- capture microdissection and molecular biology. Cancer Sci 2011, 102:1921-1927.
46. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
47. Yu F., Li J., Chen H., Fu J., Ray S., Huang S., et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011, 30:2161-2172.
48. Cittelly D.M., Finlay-Schultz J., Howe E.N., Spoelstra N.S., Axlund S.D., Hendricks P., et al. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 2013, 32:2555-2564.
49. Chen Y., Shi L., Zhang L., Li R., Liang J., Yu W., Sun L., et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008, 283:17969-17978.
50. Festuccia N., Osorno R., Halbritter F., Karwacki-Neisius V., Navarro P., Colby D., et al. Esrrb is a direct nanog target gene that can substitute for nanog function in pluripotent cells. Cell Stem Cell 2012, 11:477-490.
51. Van Den Berg D.L.C., Zhang W., Yates A., Engelen E., Takacs K., Bezstarosti K., et al. Estrogen-related receptor beta interacts with oct4 to positively regulate nanog gene expression. Mol Cell Biol 2008, 28:5986-5995.
52. Ross-Innes C.S., Stark R., Teschendorff A.E., Holmes K.A., Ali R.H., Dunning M.J., et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
53. Deblois G., Giguere V. Reprogramming clinical outcome. Nature 2012, 481:275-276.